Nkarta (NASDAQ:NKTX) Price Target Cut to $14.00 by Analysts at Mizuho

Nkarta (NASDAQ:NKTX - Free Report) had its price target decreased by Mizuho from $16.00 to $14.00 in a research report report published on Tuesday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other equities analysts have also weighed in on the company. William Blair reissued a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Stifel Nicolaus decreased their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. Finally, Needham & Company LLC lowered their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $14.33.

Nkarta Stock Performance

NKTX traded up $0.02 during midday trading on Tuesday, reaching $2.01. 224,389 shares of the company were exchanged, compared to its average volume of 1,059,194. The company has a market cap of $142.27 million, a price-to-earnings ratio of -1.06 and a beta of 0.72. Nkarta has a one year low of $1.31 and a one year high of $8.23. The company's fifty day moving average price is $1.83 and its 200 day moving average price is $2.07.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.01. As a group, sell-side analysts anticipate that Nkarta will post -1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in shares of Nkarta by 4.1% in the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after acquiring an additional 8,883 shares during the period. JPMorgan Chase & Co. lifted its stake in Nkarta by 138.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after purchasing an additional 1,474,560 shares in the last quarter. Deutsche Bank AG lifted its stake in Nkarta by 26.1% in the 4th quarter. Deutsche Bank AG now owns 43,157 shares of the company's stock worth $107,000 after purchasing an additional 8,946 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock valued at $60,000 after purchasing an additional 7,030 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Nkarta by 110.1% during the 4th quarter. Bank of America Corp DE now owns 380,444 shares of the company's stock valued at $947,000 after purchasing an additional 199,345 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.